BCM
INFI

Bridgeway Capital Management’s Infinity Pharmaceuticals, Inc. INFI Stock Holding History

Bridgeway Capital Management’s Portfolio INFI Stock Details INFI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-249,000
Closed -$138K – 1441
2022
Q4 		$138K Hold
249,000
– – ﹤0.01% 1167
2022
Q3 		$296K Hold
249,000
– – 0.01% 1043
2022
Q2 		$157K Sell
249,000
-31,000
-11% -$23.8K ﹤0.01% 1143
2022
Q1 		$319K Buy
280,000
+140,000
+100% +$167K 0.01% 1056
2021
Q4 		$315K Sell
140,000
-263,100
-65% -$660K 0.01% 1093
2021
Q3 		$1.38M Sell
403,100
-142,200
-26% -$438K 0.03% 733
2021
Q2 		$1.63M Buy
545,300
+134,500
+33% +$426K 0.03% 699
2021
Q1 		$1.33M Sell
410,800
-8,500
-2% -$28.4K 0.02% 767
2020
Q4 		$889K Hold
419,300
– – 0.02% 773
2020
Q3 		$491K Hold
419,300
– – 0.01% 891
2020
Q2 		$379K Buy
419,300
+9,300
+2% +$8.86K 0.01% 953
2020
Q1 		$343K Sell
410,000
-86,900
-17% -$101K 0.01% 882
2019
Q4 		$477K Hold
496,900
– – 0.01% 1010
2019
Q3 		$512K Hold
496,900
– – 0.01% 952
2019
Q2 		$894K Buy
496,900
+54,400
+12% +$87.6K 0.01% 771
2019
Q1 		$832K Buy
442,500
+163,500
+59% +$239K 0.01% 829
2018
Q4 		$329K Sell
279,000
-180,000
-39% -$324K ﹤0.01% 1109
2018
Q3 		$1.24M Hold
459,000
– – 0.01% 795
2018
Q2 		$877K Hold
459,000
– – 0.01% 925
2018
Q1 		$964K Hold
459,000
– – 0.01% 858
2017
Q4 		$932K Hold
459,000
– – 0.01% 863
2017
Q3 		$610K Buy
459,000
+250,000
+120% +$310K 0.01% 1037
2017
Q2 		$328K Sell
209,000
-80,000
-28% -$154K ﹤0.01% 1192
2017
Q1 		$933K Sell
289,000
-4,800
-2% -$11.8K 0.01% 836
2016
Q4 		$397K Hold
293,800
– – 0.01% 1160
2016
Q3 		$458K Buy
+293,800
New +$451K 0.01% 1124

Other funds holding INFI

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CC
Carlson Capital Dallas, Texas $318M AUM 27.64% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
E
Ergoteles New York $68.2M AUM 36.16% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bridgeway Capital Management's INFI Position: Q1 2023 in Review

Bridgeway Capital Management sold out of Infinity Pharmaceuticals, Inc. (INFI) in Q1 2023, closing a stake of 249,000 shares — an estimated $138K sold.

Bridgeway Capital Management first reported a position in INFI in Q3 2016 and held it in 26 quarters. The position peaked at $1.63M in Q2 2021. 53 funds tracked by Wall St. Rank hold INFI as of Q1 2023.

  • Bridgeway Capital Management reported no remaining Infinity Pharmaceuticals, Inc. position as of Q1 2023 after selling out during the quarter.
  • Bridgeway Capital Management sold 249,000 Infinity Pharmaceuticals, Inc. shares in Q1 2023, an estimated $138K.
  • Bridgeway Capital Management first reported a position in Infinity Pharmaceuticals, Inc. in Q3 2016 and held it in 26 quarters.
  • Bridgeway Capital Management's Infinity Pharmaceuticals, Inc. position peaked at $1.63M in Q2 2021.
  • 53 funds tracked by Wall St. Rank held Infinity Pharmaceuticals, Inc. as of Q1 2023.

Based on Bridgeway Capital Management's 13F filing for Q1 2023, filed 15 May 2023.